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Abstract 1 
Background: Variation in induced models of autoimmunity has been attributed to the housing 2 
environment and its effect on the gut microbiota. In Graves’ disease (GD), autoantibodies to 3 
the thyrotropin receptor (TSHR) cause autoimmune hyperthyroidism. Many GD patients 4 
develop Graves’ orbitopathy (GO) characterized by orbital tissue remodeling including 5 
adipogenesis. Murine models of GD/GO would help delineate pathogenetic mechanisms and 6 
although several have been reported most lack reproducibility. A model comprising 7 
immunization of female BALBc mice with a TSHR expression plasmid using in vivo 8 
electroporation, was reproduced in two independent laboratories. Similar orbital disease was 9 
induced in both centers, but differences were apparent (e.g. hyperthyroidism in Center 1 but 10 
not Center 2).  We hypothesized a role for the gut microbiota influencing the outcome and 11 
reproducibility of induced GO. 12 
Results: We combined metataxonomics (16S rRNA gene sequencing) and traditional microbial 13 
culture of the intestinal contents from the GO murine model, to analyze the gut microbiota in 14 
the two centers. We observed significant differences in alpha, beta-diversity and in the 15 
taxonomic profiles, e.g. Operational Taxonomic Units (OTUs) from the genus Lactobacillus 16 
were more abundant in Center 2, Bacteroides and Bifidobacterium counts were more abundant 17 
in Center 1 where we also observed a negative correlation between the OTUs of the genus 18 
Intestinimonas and TSHR autoantibodies. Traditional microbiology largely confirmed the 19 
metataxonomics data and indicated significantly higher yeast counts in Center 1 TSHR-20 
immunized mice. We also compared the gut microbiota between immunization groups within 21 
the Center 2, comprising the TSHR or βgal control immunized mice and naïve untreated mice. 22 
We observed a shift of the TSHR immunized mice bacterial communities described by the 23 
beta-diversity weighted Unifrac. Furthermore, we observed a significant positive correlation 24 
 2 
between the presence of Firmicutes and orbital-adipogenesis specifically in TSHR-immunized 25 
mice. 26 
Conclusions: The significant differences observed in microbiota composition from BALBc 27 
mice undergoing the same immunization protocol in comparable specific-pathogen free (SPF) 28 
units in different centers support a role for the gut microbiota in modulating the induced 29 
response. The gut microbiota might also contribute to the heterogeneity of induced response 30 
since we report potential disease-associated microbial taxonomies and correlation with ocular 31 
disease. 32 
 33 
Keywords: Graves’ orbitopathy; Graves’ disease; Induced animal model; Gut microbiota; 34 
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 3 
Background 36 
The poor reproducibility of murine models of human diseases has become a puzzling 37 
phenomenon in recent decades. Apart from the genetic background of the strains used, the type 38 
of animal housing, diet and even the vendor can influence disease phenotype [1,2]. 39 
In Graves’ disease (GD) and Graves’ Orbitopathy (GO), in vivo models could help to unravel 40 
the pathogenetic mechanisms leading to autoimmunity and identify new therapeutic targets. 41 
[3]. The lack of spontaneous models of GD and GO necessitates induction of disease under 42 
laboratory conditions (reviewed in [4]). 43 
Graves’ disease is an organ-specific antibody-mediated autoimmune disease, governed by both 44 
genetic predisposition and environmental factors, in which thyroid-stimulating antibodies 45 
(TSAb) mimic the function of thyroid-stimulating hormone (TSH) to activate the thyrotropin 46 
receptor (TSHR). Moreover, the presence of thyroid-stimulating blocking antibodies (TSBAb), 47 
which inhibit the TSHR signaling cascade, and neutral antibodies to TSHR have been described 48 
in GD [5]. GD symptoms include hyperthyroidism, weight loss, heat intolerance and tremors; 49 
it affects about 2% of the population in the UK, with a female predominance. About 20% of 50 
GD patients develop an eye disease, Graves’ orbitopathy or ophthalmopathy (GO), 51 
characterized by pro-inflammatory cells and tissue remodeling (extraocular muscle 52 
inflammation, adipogenesis, over-production of extra-cellular matrix) in the orbit [6]. 53 
Several GD mouse models have been developed using different immunization protocols with 54 
no signs of concomitant eye disease as previously reviewed [4,7-8]. Ludgate and colleagues 55 
established a TSHR-induced GO model by genetic immunization; i.e. injecting a TSHR 56 
expression plasmid [9]. Mice developed thyroiditis plus some aspects of GO and disease could 57 
be transferred to naive recipients using the TSHR-primed T cells from the genetically 58 
immunized mice. However, the model could not be reproduced in a different animal unit 59 
(neither was specific-pathogen free (SPF)) and the TSHR-induced disease was quite distinct 60 
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from that previously described, which the authors postulated might be due to microorganisms 61 
[10]. It has also been reported that TSHR-immunized mice from a conventional environment 62 
had higher and more persistent TSAb levels than mice in SPF units [11]. 63 
Recently, Berchner-Pfannschmidt and colleagues reported the induction of GO-like disease in 64 
two independent SPF units [12]. The immunization protocol utilized genetic delivery of TSHR 65 
A-subunit plasmid by close field electroporation, which leads to features of GD accompanied 66 
by symptoms of eye disease, such as adipogenesis and inflammatory infiltrates in the orbit 67 
[7,13]. Controls received a plasmid encoding the β-galactosidase (βgal) gene delivered by the 68 
same procedure. Most aspects of the model were reproduced successfully, however, there was 69 
heterogeneity in induced disease and differences in thyroid function in the animals undergoing 70 
experimental GO in the two locations [12]. 71 
Over the years the gut microbiota has been associated with several diseases [14-17] and its 72 
confounding role in establishing or reproducing disease phenotype in murine models has also 73 
been proposed [18].  74 
The murine model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), 75 
seems to be highly influenced by the gut microbiota. Oral antibiotic immunization and 76 
consequent depletion of the gut bacteria, before disease induction, resulted in protection from 77 
disease development, along with reduction in pro-inflammatory mediators such as IL-17 and 78 
an increased Th2-immune response [19]. On the contrary, the intestinal monocolonization of 79 
germ free mice (sterile) with segmented filamentous bacteria (SFB) restored the disease 80 
phenotype, along with an increased number of Th17 cells in the CNS, suggesting a direct 81 
interplay of the gut microbiota and the immune response in EAE development [20].  82 
Based on these observations, we hypothesized that the gut microbiota itself might play a major 83 
role not only in the establishment, but also in the reproducibility of the GO animal model 84 
described above. The presence or absence not only of pathogens, but also of symbiotic and 85 
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commensal bacteria can favor an immune response more prone to inflammation and conducive 86 
to autoimmunity [21].  87 
We aimed to characterize, for the first time, the gut microbiota of the GD/GO models via a 88 
combination of metataxonomics (16S rRNA gene sequencing) and traditional microbial culture 89 
approaches. We compared the gut contents of TSHR immunized mice from the two centers to 90 
understand whether variation in gut composition could explain differences in the disease 91 
induced. Within one center, we then characterized the gut microbiota between different 92 
immunizations (TSHR and βgal) and compared them with untreated mice, to determine 93 
whether the gut microbiota can influence the outcome and correlate with disease features.  94 
Materials and methods 95 
GO preclinical mouse model samples 96 
Mouse samples used in the present work were obtained from a recent study [12], conducted in 97 
parallel in two independent animal housing units, under comparable SPF conditions. Animal 98 
procedures in center 1 were reviewed and approved by the Ethical Committee of King’s 99 
College London and conducted with Personal and Project licenses under United Kingdom 100 
Home Office regulations. Animal procedures in center 2 were reviewed and approved by North 101 
Rhine Westphalian State Agency for Nature, Environment and Consumer Protection 102 
(LANUV), Germany. Samples from the animal unit of King’s College London (UK) will be 103 
referred to as the “Center 1” and included a total of 5 TSHR-immunized mice (TSHR). Samples 104 
from the University of Duisburg-Essen (Germany) will be referred to as the “Center 2”, 105 
including 10 TSHR-immunized (TSHR), 8 βgal plasmid controls (βgal) and 6 untreated mice 106 
(included as a background control), as shown in Table 1. 107 
The GO immunization protocol has been previously described [13]. Briefly, 6-8 weeks old 108 
BALB/cOlaHsd female mice were immunized via intramuscular injection into each biceps 109 
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femoris muscle [22] and electroporation of either the eukaryotic expression plasmid 110 
pTriEx1.1Neo-hTSHR (hTSHR289) (TSHR group) or the control plasmid pTriEx1.1Neo-β-111 
gal (plasmid-control, βgal group). All animals, whether TSHR or βgal controls, received a total 112 
of four plasmid injections at three week-intervals of the experiment (0, 3, 6, 9 weeks).  113 
Each mouse was anesthetized using isoflurane with a properly calibrated vaporizer throughout 114 
the immunization procedure (injection and electroporation). After the immunization, mice were 115 
carefully transferred to a recovery cage until fully recovered.  116 
Mice in Center 1 were maintained conventionally in open cages in one room and co-housed at 117 
a maximum of 3 animals per cage. In Center 2, the mice were co-housed according to their 118 
immunizations, 2-4 animals per individually ventilated cage in one room. All mice were 119 
provided by different outlets of the same supplier (Harlan Ltd or Harlan laboratories BV). In 120 
both centers, mice received autoclaved water and had been fed ad libitum similar commercial 121 
chow from different suppliers (Rat and Mouse no.1 Maintenance from Special Diet Services, 122 
LBS Biotech UK for Center 1 and Rat/Mouse Maintenance V1534-300 from Ssniff 123 
Spezialadiaten GmbH, Germany, for Center 2). Also the cage bedding was from different 124 
suppliers. 125 
All immunized and control mice in both locations were sacrificed nine weeks after the last 126 
immunization (18 weeks) to permit the development of the chronic phase of the disease in the 127 
TSHR group (Additional file 1: Figure S1). 128 
After sacrifice, murine intestines were snap-frozen and stored in sterile containers at −80°C. 129 
For subsequent analysis, whole intestines were thawed and directly afterwards placed on a 130 
sterile padding. The organs were dissected into two or three parts and the content of all parts 131 
was scratched out from oral to aboral end with a sterile inoculation loop resulting in one sample 132 
per mouse, which was collected in a sterile container and frozen at -80°C until needed. Within 133 
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the Center 2 only, fecal pellets of βgal and TSHR immunized mice were also collected before 134 
each injection (week 0, 3, 6, 9). Total DNA was extracted from fecal pellets as described below. 135 
Methods for: i) the evaluation of clinical symptoms, ii) the determination of the thyroid 136 
hormone thyroxine blood levels (fT4) and TRAB (both stimulating TSAb and blocking 137 
TSBAb) antibodies, iii) the measurement of the expansion of fat cells (adipogenesis) and 138 
muscular atrophy in the orbit have been already described [12]. A full description of the mice 139 
involved and samples collected in the present study is represented in Table 1. 140 
 141 
Table 1 Description of the mouse groups involved in this study 142 
No. of animals Immunization Centers Source Timepoint 
5 TSHR 1 Intestinal scraping T4 
10 TSHR 2 I.S./Feces T0-T4* 
8 βgal 2 I.S./Feces T0-T4* 
6 Untreated 2 I.S./Feces T4° 
 
A total of 23 female BALB/cOlaHsd, 6-8 weeks old mice were challenged either with the pTriEx1.1Neo-143 
hTSHR to induce disease (TSHR group) or with pTriEx1.1Neo-β-gal as a plasmid control group (βgal 144 
group). Independent SPF animal units were based in London (Center 1) and Essen (Center 2). An untreated 145 
group of 6 mice has been included as a background control. Samples collection comprised of intestine 146 
scraping (I.S.) from Center 1 and both fecal pellets and I.S. within the Center 2. *Fecal pellets of βgal and 147 
TSHR immunized mice have been collected before any immunization (T0) and during the time course of the 148 
immunization protocol until the sacrifice (T4), as represented in Additional file 1: Figure S1. °Untreated 149 
mice were sampled at T4 before (fecal) and after the sacrifice (intestinal scraping).  150 
Traditional microbial cultures of mouse gut contents  151 
A total of 29 scraped intestinal samples (Table 1) derived from Center 1 and Center 2 were 152 
analyzed. One gram of feces per mouse was diluted in 9 ml pre-reduced maximum recovery 153 
diluent (CM0733, Oxoid, Basingstoke, United Kingdom) with 20% v/v glycerol and the 154 
solution was mixed by vortexing for 5 s. Afterwards, 10-fold serial dilutions were prepared, 155 
and 100µl of each dilution was plated onto different culture media under aerobic or anaerobic 156 
conditions (Anaerobic Workstation, AW400SG, Elektrotek, Keighley, West Yorkshire, United 157 
Kingdom). Specific media, culture conditions and dilution used to isolate different bacteria are 158 
listed in Additional file 2.  159 
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Bacteria were identified by Gram staining, colony morphology, the presence of spores, catalase 160 
reaction and partially by the API system (BioMerieux, Marcy-l’Étoile, France). Viable 161 
bacterial cell counts were enumerated and all counts were recorded as the numbers of log 10 162 
colony forming units per gram of sample. Counts data were Box-Cox transformed before 163 
statistical analysis [23]. Mouse groups were compared through the Analysis of variance (one-164 
way ANOVA) and Tukey’s multiple comparisons test with adjusted P values.  165 
Extraction of total DNA from gut contents and feces and 16S rRNA gene sequencing 166 
A total of 29 scraped intestinal samples and 96 fecal pellets were individually placed in 2mL 167 
tubes prefilled with 0.1mm silica and zirconia bead mix (Benchmark Scientific, Edison, USA), 168 
dissolved in 1mL InhibitEX buffer (Qiagen Ltd, West Sussex, UK) and vortexed until 169 
homogenized. A bead-beating step (Beadbug microcentrifuge homogenizer, Benchmark 170 
Scientific, USA) was applied for 3 x 60sec at 5m/s with 5 min rest in-between. The DNA 171 
extraction has been performed with QiAmp Fast DNA Stool Mini kit (Qiagen Ltd, UK), 172 
following the manufacturer’s instruction. Total genomic DNA was eluted in sterile 173 
microcentrifuge tubes and quantified by Qubit Fluorimetric Quantitation (ThermoFisher 174 
Scientific Ltd, UK), following manufacturer's instructions. DNA aliquots were kept at -20°C 175 
until used. Sequencing of the variable regions of the 16S rRNA gene was performed at 176 
Research and Testing Laboratory LLC. (Lubbock, Texas, USA). Primers used to amplify the 177 
V1-V2 regions of 16S rRNA gene were: 28F (5’-GAGTTTGATCNTGGCTCAG-3’) and 388R 178 
(5’-TGCTGCCTCCCGTAGGAGT-3’). Sequencing was performed using an Illumina Miseq 179 
(Illumina, San Diego, USA), with 10K paired-end sequencing protocol.  180 
Processing and statistical analysis of metataxonomic data 181 
Processing of the sequences was performed using Mothur v1.36, to reduce possible PCR effects 182 
and to cluster sequences into Operational Taxonomic Units (OTUs) at the 97% identity cut-off 183 
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and provide the taxonomic annotations [24]. Paired-end reads (R1 and R2) were joined for each 184 
sample using the Mothur function “make.contigs” and trimmed at the 2.5%-tile and 97.5%-tile 185 
on the distribution lengths of the amplicons. Sequences with any ambiguities (i.e. Ns) were 186 
removed by setting parameter N=0. Filtered sequences were aligned against the SILVA 16S 187 
rRNA gene reference database (http://www.arb-silva.de). Removal of chimera sequences was 188 
done with the Uchime tool [25]; singleton and non-bacterial sequences (e.g. Archaea, 189 
Eukaryotic, Chloroplast and Mitochondria) have been removed from the analysis. The 190 
taxonomic assignment from phylum to genus level of the processed sequences was done using 191 
the Ribosomal Database Project (RDP) Naïve Bayesian Classifier, using Trainset 14 with a 192 
cut-off of 80% [26]. FastTree (version 2.1.7) has been used to build a phylogenetic tree, using 193 
an approximated maximum likelihood solved by Jukes-Cantor evolutionary model [27]. To 194 
reduce the effect of possible different sampling methods and to obtain comparable sequencing 195 
libraries, each sample library has been subsampled based on the smallest library size. OTUs 196 
with less than 10 counts have been excluded from the dataset and grouped as “OTU_low”, and 197 
the analysis has been performed collapsing OTUs at the phylum-genus levels. Statistical 198 
analysis was performed in R (Version 3.2.2) and STAMP tool for metataxonomic data analysis 199 
[28].  200 
Alpha diversity indices (Observed OTUs, Chao1, ACE and Shannon) were calculated within 201 
samples from Mothur and tested for association with covariates (e.g. locations and 202 
immunizations) using a linear model, followed by Tukey’s Honest Significant Difference 203 
(HSD) post-hoc analysis.  204 
Beta diversity was estimated using the Unifrac weighted distance to compare bacterial 205 
communities among samples [29], and represented in a Non-Metric Dimensional Scaling 206 
(NMDS) plot. The permutational multivariate analysis of variance (PERMANOVA) was 207 
calculated through the Adonis function [30] in R Vegan package (using 999 permutations) and 208 
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was used to test the association between the microbiota composition and the covariates (e.g. 209 
location of the laboratories or immunizations).  210 
The hierarchical clustering of genera was performed using the Spearman distance and the Ward 211 
agglomeration method. Statistical tests with P≤0.05 were considered as significant. 212 
Over multiple timepoints, the effects of time, immunizations and their interactions, have been 213 
estimated on the fecal microbiota composition, all by means of the following linear model:  214 
𝑦𝑖𝑗𝑘 = 𝜇 + 𝑇𝑖𝑚𝑒𝑖 +  𝐼𝑚𝑚𝑢𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛𝑗 + (𝑇𝑖𝑚𝑒 ∗  𝐼𝑚𝑚𝑢𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛)𝑖𝑗 + 𝑒𝑖𝑗𝑘 215 
where y is the vector of either alpha-diversity Chao or Shannon indices, or of the 216 
Firmicutes/Bacteroidetes ratio calculated from the relative abundances in each sample at each 217 
timepoint; μ is the overall mean; time is the effect of timepoint in classes (T0, T1…T4); 218 
immunization is the type of immunization (either the TSHR or βgal). The factorial interaction 219 
between immunization and time has also been included in the model; e is the vector of residual 220 
effects. Comparison between βgal and TSHR immunizations at each timepoint was made using 221 
the pairwise T-test with Benjamini-Hochberg correction for false rate discovery (FDR).   222 
To test differences in phylum and genus counts between immunizations and timepoints, the 223 
same model was used in the generalized linear model (GLM) implemented in the EdgeR 224 
package [31]. Pairwise comparisons of phylum and genus counts between timepoints and 225 
immunizations have been assessed with Fisher’s Exact Test in EdgeR package. 226 
Correlations of either the taxonomy counts (phylum and genus relative abundances) or the 227 
microbial counts from the traditional culture approach and disease features, such as anti-TSHR 228 
antibodies and thyroid hormone thyroxine levels (fT4), orbital adipogenesis or muscular 229 
atrophy values, were estimated using the Spearman correlation coefficient (Rho) and 230 
represented in a correlation plot, using the R Corrplot package. Additional statistical methods 231 
are described in Additional file 2.  232 
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Results  233 
Sequencing metrics 234 
From 16S rRNA gene sequencing (V1-V2 regions), a total of 5,333,798 reads were obtained 235 
which reduced to 4,047,186 reads after quality filtering. Following alignment, we obtained an 236 
average of 20,534 reads per sample, ranging from 3,502 to 134,901. Subsampling per library 237 
size resulted in a 96% average coverage per OTU definition at 3,052 reads per sample. The 238 
averaged coverage and subsampling was sufficient to describe gut bacterial communities 239 
according to sequence-based rarefaction curves (data not shown). 240 
We identified a total of 4,281 OTUs: 1,037 OTUs had more than 10 counts across samples, and 241 
were retained.  242 
Comparative analysis of the gut microbiota of GO preclinical mouse models in different 243 
centers  244 
To assess whether the microbiota has an impact on the GO mouse model in different 245 
laboratories, we compared the gut microbial contents of 5 TSHR mice from Center 1 and 10 246 
TSHR immunized BALB/c female mice from Center 2, after sacrifice (T4).  247 
Comparison of the alpha diversity indices showed a significant reduction in the richness 248 
(P=0.01), but not in the diversity of the Center 2 microbial community (P>0.05, Figure 1A). 249 
The gut microbiota composition from the two centers showed a good separation according to 250 
the Spearman distance and Ward hierarchical clustering (Figure 1B), and a PERMANOVA test 251 
on the weighted Unifrac distances revealed a spatial difference between bacterial communities 252 
(P=0.005 with 999 permutations, Figure 1C). 253 
At a phylum level, Bacteroidetes and Firmicutes were the most represented of the 7 phyla 254 
identified, with no differences between them in the two centers (P=0.99). Lactobacillaceae, 255 
Ruminococcaceae and Porphyromonadaceae families were more abundant in Center 2 than in 256 
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Center 1 TSHR mice (P<0.01, Figure 1D). We observed significant differences in the 257 
abundance of eighteen genera between the two centers, as detailed in Table 2.  258 
From the traditional microbial culture of the gut contents, we observed differences in yeasts 259 
(P=0.03186), Bacteroides (p<0.0005) and total anaerobes (P=0.00081) counts, which were 260 
found to be enriched in the Center 1 compared with the Center 2 TSHR mice (Table 3). Cultures 261 
from mouse intestinal scraping of the Center 2 did not contain any total clostridia, Bacteroides 262 
or yeasts, and we were able to culture enterobacteria, E. coli and coliforms from only one 263 
mouse from this group. E.coli and coliforms were also the least abundant in the Center 2 TSHR 264 
mice (Figure 1E). Furthermore, since Yersinia enterocolitica has been implicated in GD 265 
pathogenesis [32] we used selective agar plates for Yersinia sp. but no Yersinia colonies grew. 266 
  267 
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Table 2 Genera differentially abundant between Center 1 (n=5) and Center 2 (n=10) TSHR 268 
immunized mice intestinal scraped samples 269 
 270 
Genera  Center 1: mean freq. (%) 
Center 2: mean freq. 
(%) 
P values  
Allobaculum 1.001 0.003 0.042 
Alloprevotella 6.135 0.432 0.003 
Bacteroides 9.370 1.525 0.017 
Bifidobacterium 0.668 0.006 0.003 
Clostridium XI 0.840 0.000 0.005 
Coprobacter 1.835 4.226 0.033 
Fusicatenibacter 0.989 3.295 0.032 
Guggenheimella 0.006 0.169 0.011 
Helicobacter 0.200 0.000 0.024 
Intestinimonas 0.097 0.861 0.000 
Lactobacillus 2.304 18.632 0.030 
Lactonifactor 0.023 0.401 0.025 
Meniscus 1.149 0.000 0.000 
Oscillibacter 0.640 1.748 0.011 
Parabacteroides 0.292 0.031 0.015 
Pseudoflavonifractor 0.154 0.466 0.028 
Rikenella 3.921 1.216 0.004 
Turicibacter 3.629 0.000 0.002 
    
 271 
ANOVA with Tukey’s HSD post-hoc analysis (95% confidence interval), generated with STAMP. 272 
Mean freq: mean frequency (%).  273 
 
Table 3 Traditional microbiology results from TSHR-immunized mouse intestinal scraping 274 
from Center 1 (n=5) and Center 2 (n=10)  275 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b.d.l.: below detection limit. Detection limits are the following according to the agar used: 1000 CFU/g 276 
feces for Bacteroides, 100 CFU/g feces for E.coli and coliforms as well as for enterobacteria, and 10 277 
Microbial target Center 1: mean counts  Center 2: mean counts      P values 
Bacteroides 1.15E+05 b.d.l. 0.000 
Bifidobacteria 6.41E+06 1.32E+06 0.057 
Coliforms 3.27E+02 1.15E+03 0.453 
E.coli  b.d.l. 8.45E+02 0.499 
Enterobacteria b.d.l. 6.82E+02 0.499 
Enterococci 1.74E+05 6.10E+06 0.247 
Lactobacilli 1.93E+06 4.68E+06 0.725 
Staphylococci 1.31E+05 3.77E+05 0.175 
Total aerobes 4.18E+05 9.90E+06 0.370 
Total anaerobes 6.75E+06 7.39E+05 0.001 
Total Clostridia 2.46E+04 b.d.l. 0.165 
Yeast 8.72E+01 b.d.l. 0.031 
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CFU/g feces for total clostridia and yeasts, respectively. Microbiological counts were Box-Cox 278 
transformed. P values obtained by linear regression.  279 
Gut microbiota differences in immunized and control mice within the Center 2 280 
To observe the possible contribution of the gut microbiota in the disease, we compared the gut 281 
microbiota composition between immunization groups in mice within the Center 2. No 282 
significant differences were observed in alpha diversity indices among immunizations, apart 283 
from the Abundance-based Coverage Estimator (ACE) index between untreated and TSHR 284 
groups (Figure 2A, P=0.01). The ACE index relies on the presence of rare OTUs [33], which 285 
were more abundant in the untreated group compared to the plasmid-immunized mice. The 286 
βgal group showed a slightly skewed distribution of the Shannon index when compared to the 287 
others; however, the post-hoc comparison was not significant. 288 
The non-metric dimensional scaling (NMDS) of the weighted Unifrac distances matrix showed 289 
a separation of the three immunization groups, also confirmed by the permutation test (P<0.01, 290 
999 permutations; Figure 2B). βgal bacterial communities were closer to those of the untreated 291 
mice, while we observed a spatial shift of the TSHR immunized bacterial communities. 292 
OTUs from Bacteroidetes and Firmicutes phyla were the most abundant among the phyla 293 
identified (Figure 2C) and showed a different distribution pattern among immunized groups. 294 
In particular, Firmicutes counts were higher in TSHR immunized mice (P=0.05) and 295 
Bacteroidetes were found to be higher in the untreated group (P=0.012). At a genus level, eight 296 
genera were differentially abundant between TSHR and βgal groups; three genera between 297 
TSHR and the untreated group and four genera between βgal and the untreated group 298 
(Additional file 3: Table S1). We found an enrichment of OTUs of Acetitomaculum genus in 299 
the βgal group compared to both TSHR (P=0.004) and the untreated group (P=0.003); an 300 
enrichment of Lactobacillus OTUs in the TSHR compared to the untreated group (P=0.018) 301 
and a reduction of Bacteroides counts in TSHR when compared to the βgal group (P=0.047). 302 
However, no significant differences were observed among immunized groups and in pairwise 303 
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comparisons generated by the traditional bacterial culturing approach (Additional file 3: Table 304 
S2). 305 
In the scraped intestinal samples, we did not observe a cage effect on the composition of the 306 
large intestine microbiota (PERMANOVA P>0.05; Figure 2D). 307 
Dynamics of fecal microbiota during the immunization protocol 308 
To assess whether the immunization plasmids and the duration of the protocol could have 309 
influenced the gut microbiota composition, we sequenced the bacterial 16S rRNA gene from 310 
the fecal pellets of the βgal and TSHR group from the baseline (T0) for 18 weeks afterwards, 311 
until the end of the experiment (T4).  312 
We observed a significant increase of the richness (Chao index, figure 3A; P=0.02) and the 313 
diversity (Shannon index, figure 3B) over time, which was less apparent in the TSHR 314 
immunized group. Significant differences regarding of richness between TSHR and βgal have 315 
been observed at T4 (P=0.027, Table 4). The Shannon index of diversity, on the contrary, was 316 
significantly different between TSHR and βgal immunization at T1 (P=0.023, Table 4).  317 
Table 4 Summary of the statistics from the time-course analysis of the fecal microbiota during 318 
the immunization protocol (T0-T4) and between immunizations (βgal and TSHR)  319 
 320 
Index 
ANOVA model TSHR vs. βgal group 
Immunization Time Time*Immunization T0 T1 T2 T3 T4 
Chao  0.006 0.02 0.8 0.75 0.066 0.28 0.33 0.027 
Shannon 0.054 0.28 0.47 0.44 0.023 0.35 0.35 0.29 
Firm:Bact 0.406 0.0003 0.16 0.39 0.028 0.46 0.2 0.26 
 321 
Firm:Bact, Firmicutes/Bacteroidetes ratio. ANOVA model as previously described. Pairwise 322 
comparison between βgal and TSHR in each time point has been made with a pairwise T-test with 323 
Benjamini-Hochberg correction for FDR. 324 
 325 
The murine fecal microbiota comprised Bacteroidetes and Firmicutes phyla predominantly 326 
(Figure 4C); followed by Tenericutes, Proteobacteria Deferribacteres and Candidatus 327 
Saccharibacteria phyla. The Firmicutes/Bacteroidetes ratio has been used to describe the shift 328 
in the gut microbiota associated with ageing [34] and also in disease conditions such as obesity 329 
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[35]. The ratio showed differences amongst the timepoints of the experimental procedure 330 
(P<0.01) and between TSHR and the βgal group after three weeks from the first injection (T1, 331 
P=0.011; Figure 3C).  332 
We fitted a generalized linear model (GLM) to compare the taxonomic counts at different 333 
timepoints within each group independently (either TSHR or βgal). Thirty-four genera have 334 
been identified as differentially abundant among all timepoints in the TSHR immunized group 335 
(Additional file 4: Table S1), while 25 were found in the βgal group (Additional file 4: Table 336 
S2). We observed differences in the taxonomic profile between TSHR and βgal groups at each 337 
timepoint using an exact test (EdgeR). Once again T1 was identified as the timepoint with the 338 
highest number of genera differentially expressed, as illustrated by the diversity indices 339 
(Additional file 4: Table S3). 340 
In contrast to data obtained from the gut microbiota (Figure 2D), a cage effect was observed in 341 
the fecal microbiota, in particular, in interaction with time (P=0.001) and immunization 342 
(P=0.002; Additional file 5: Figure S1). The latter is probably due to the mice being caged 343 
according to the type of plasmid injection they received, but we also observed a significant 344 
difference within the same immunization group (e.g. TSHR in cage 4 and cage 5, P=0.01).  345 
Correlating the gut microbiota composition with clinical features and differences in GO 346 
development  347 
We then investigated possible correlations between disease features, such as anti-TSHR 348 
antibodies, thyroxine levels (fT4), orbital adipogenesis and muscular atrophy, and the gut 349 
microbiota composition to determine whether it contributes to the heterogeneity of induced 350 
responses, summarized in Additional file 1: Table S1.  351 
Within the Center 1 TSHR-immunized group, we found that OTUs from Firmicutes and 352 
Bacteroidetes negatively correlated to each other (Rho=-1, P<0.0001). A positive correlation 353 
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between levels of TSAb and Deferribacteres phylum, which include one-genus Mucispirillum, 354 
was found (Rho=0.92, P=0.028; Figure 4A).  355 
From those genera differentially abundant between TSHR-immunized mice from Center 1 and 356 
Center 2 (Table 2), identified via metataxonomics, we observed a strong negative correlation 357 
of the Firmicutes genus Intestinimonas and the levels of TSBAb in the Center 1 (Rho=-0.89, 358 
P<0.05), but not in the Center 2 counterpart (Figure 4B). No significant correlation was 359 
observed between OTUs from the genus Intestinimonas and levels of TSAb or levels of free 360 
thyroxine hormone (fT4; data not shown).  361 
On the contrary, the Box-Cox transformed counts from the traditional microbiology did not 362 
show any significant correlation with the disease features described (data not shown). 363 
Within the Center 2, Bacteroidetes and Firmicutes negatively correlated to each other (Rho=-364 
0.99, P<0.0001; Figure 5A). We also found a significant positive correlation (Rho=0.6, 365 
P=0.009) between the OTUs from the Firmicutes and the orbital adipogenesis value and a 366 
negative correlation of this value with the phylum Bacteroidetes (Rho= -0.57, P=0.014). As 367 
expected, these correlations were specific to the TSHR immunized mice (Figure 5B). The 368 
correlation pattern we found (Firmicutes positively correlated, Bacteroidetes negatively 369 
correlated) was also recapitulated at the genus level. Among the genera of the Firmicutes, three, 370 
within the Clostridia family (Butyricicoccus, Parvimonas and Fusibacter) and the genus 371 
Lactobacillus were correlated positively with adipogenesis; while three Bacteroidetes genera 372 
(Anaerophaga, Paraprevotella and Tannerella) correlated negatively with the orbital 373 
adipogenesis values (Figure 5C). 374 
A strong positive correlation (Rho=0.82, P=0.007) was observed between orbital adipogenesis 375 
and the total anaerobes counts obtained from the traditional microbial cultures of TSHR 376 
immunized mice, but not in the controls (Figure 5D). Moreover, from the traditional microbial 377 
cultures data, we observed correlations with other disease features, specifically in the TSHR 378 
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group. We observed strong positive correlations between the muscular atrophy values and the 379 
cluster of lactobacilli (Rho=0.74, P=0.03), enterococci (Rho=0.8, P=0.02), bifidobacteria 380 
(Rho=0.76, P=0.03) and coliforms (Rho=0.73, P=0.04). Levels of free thyroxine (fT4) were 381 
positively correlated with lactobacilli (Rho=0.64, P=0.05) and staphylococci (Rho=0.77, 382 
P=0.016).  383 
Discussion   384 
Animal models have been invaluable in dissecting the mechanisms causing loss of immune 385 
tolerance leading to autoimmune conditions such as GD. Thus, we aimed to test the hypothesis 386 
that the gut microbiota may affect both outcome and reproducibility of induced autoimmune 387 
disease, such as reported in the recent research article of Berchner-Pfannschmidt and co-388 
workers [12]. 389 
We observed significant differences in the diversity and spatial organization of the gut 390 
microbiota of female TSHR-immunized BALBc mice in two independent SPF units. We also 391 
demonstrated disease-associated microbial taxonomies and correlation with ocular disease, 392 
suggesting that the gut microbiota have contributed to the heterogeneity of induced response 393 
in the two locations, which further supports our hypothesis. 394 
Animals were maintained in similar conditions. We are confident that there were no infections 395 
ongoing at the moment of sampling, since animals in both centers were routinely tested for the 396 
presence of viruses, mycoplasma and parasites (see Additional File 1: Table S2); moreover, 397 
housing facilities had comparable SPF conditions. Animals were from the same supplier but in 398 
different countries (Harlan Ltd. for Center 1 and Harlan Lab. BV for Center 2), had received 399 
autoclaved water and had been fed similar commercial chow, with the exception that food 400 
pellets provided in Center 2 contained twice the amount of iodide compared to Center 1 food 401 
(see Additional File 1: Table S3). Although iodide excess can be associated with abnormal 402 
thyroid function, we do not consider that this dietary variation is enough to explain the results 403 
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(i.e. elevated thyroxine levels were apparent in the Center 1 but not in Center 2 mice). The 404 
effect of iodine has been studied in the NOD mouse which spontaneously develops 405 
autoimmune thyroiditis. Vecchiatti and colleagues [36] reported that excess iodine (0.2 406 
mgs/mouse/day) increased the incidence and severity of disease; however, the BALB/c mice 407 
in our study did not display thyroiditis. A transgenic NOD mouse expressing the human TSHR-408 
A subunit is able to develop antibodies to the human TSHR and this too is exacerbated by 409 
iodine excess [37] but at levels far greater than in the chow used in Centers 1 and 2. We also 410 
considered whether iodine could affect the gut microbiota, in view of its use as an antiseptic, 411 
but all the studies we found were in this context, rather than the effect of dietary iodine on 412 
symbionts. The importance of SPF conditions is indicated by a previous study which failed to 413 
reproduce a GO animal model, despite using mice from the same supplier and identical 414 
bedding, water and chow [10]. However even SPF may be inadequate since differences were 415 
found in the gut microbiota of C57BL/6 colonies bred in two different rooms of the same SPF 416 
facility [38], fortunately mice in our study were all housed in the same room. 417 
Cage effects were apparent in the fecal microbiota results, which highlight the importance of 418 
studying the gut microbiota instead when comparing autoantigen (TSHR)-immunized and 419 
control mice, which is in the close proximity of the intestinal mucosa and the immune system, 420 
enabling us to explore its relationship with disease features.    421 
We observed several disease-associated taxonomies; the abundance of the newly described 422 
butyrate-producing genus Intestinimonas [39] was reduced in the Center 1 group compared to 423 
Center 2 and correlated negatively with TSBAb. The Intestinimonas species butyroproducens 424 
has a unique ability to produce butyrate from lysine and is involved in the detoxification of 425 
Advanced Glycosylation End (AGE) products such as fructoselysin, which have been linked 426 
to type-1 diabetes [40], although we are unaware of any link between butyrate-producing 427 
bacteria and thyroid autoimmunity.  428 
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The TSHR immunized group developed some signs of GO and their gut microbiota had 429 
increased OTUs of the phylum Firmicutes but decreased Bacteroidetes compared with 430 
controls. This mirrors our preliminary data in human disease where we observed a dramatic 431 
reduction in the Bacteroides genus in GD patients when they develop GO (INDIGO 432 
publishable summarya). 433 
We also obtained a positive correlation between several Firmicutes counts, such as Clostridia 434 
and Bacilli, with orbital adipogenesis in Center 2 TSHR-immunized mice. Million and co-435 
workers have previously reported a positive correlation between OTUs from the Firmicutes 436 
and weight-gain/obesity in both animal models and humans [41]. Interestingly, the role of the 437 
genus Lactobacillus and its products in either triggering or protecting from adipogenesis has 438 
been debated and seems to be species-specific.  439 
In the present work, we could exclude a possible gain-of-weight relationship with the 440 
adipogenesis value calculated in the orbit since no changes in mouse weights have been 441 
observed during the development of the chronic phase of the disease (data not shown). 442 
Furthermore, molecular mechanisms driving obesity and orbital adipogenesis may well be 443 
different, since the latter is derived from the neural crest and the gut microbiota may have 444 
varying effects on different fat depots [42]. 445 
Our time-course analysis revealed that time had a dramatic role in shaping the fecal microbiota 446 
of the female mice which were 6-8 weeks-old at the outset and 24-26 weeks at the end of the 447 
experiment, confirming the work of McCafferty and colleagues [43]. The richness and diversity 448 
of βgal control mice increased with age but this was less apparent in TSHR immunized animals. 449 
Significant differences in microbiota composition between control and TSHR immunizations 450 
were most apparent 3 weeks after the first immunization, at the initiation of the induced 451 
immune response. 452 
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Our control group comprised mice immunized with the βgal expression plasmid in which we 453 
observed a slight skew in the microbiota richness and diversity which may be caused by the 454 
systemic overexpression of the β-galactosidase enzyme, whose natural role is in glycan 455 
metabolism, e.g. the hydrolysis of the lactose to galactose and glucose [44]. Kaneda and 456 
collaborators reported a βgal overexpression peak in the muscle fibers following 457 
electroporation from five days to 2 weeks after the injection [45].  458 
 It may be that the increased OTUs of the Firmicutes genus Acetitomaculum was specifically 459 
triggered by the product of the βgal enzymatic reaction over time (Additional file 4: Table S2). 460 
This effect merits further investigation but we are confident that the βgal vector plasmid 461 
provides the optimum control group since its microbial communities were more closely related 462 
to that of the naïve non-immunized group than to TSHR immunized mice. Of interest, TSHR-463 
immunized mice in Center 2 were more similar to TSHR-immunized mice from Center 1 464 
(P=0.2) than βgal (P=0.024), than untreated (P=0.04) mice in their own center (Additional File 465 
6: Figure S1). 466 
The results we obtained using 16S rRNA gene metataxonomics and via the traditional 467 
microbial culture approach were largely similar, with relatively few differences. Microbial 468 
cultures revealed significantly higher yeast counts (P=0.03186) in Center 2 TSHR immunized 469 
mice - which obviously could not be seen via the bacterial metataxonomics - and a nearly 470 
significant difference in the Actinobacteria genus Bifidobacterium (P=0.057), which was not 471 
detected in our metataxonomics data. Primers based on the V1-V2 regions of the 16S rRNA 472 
gene did not detect Bifidobacterium OTUs. Consequently, we applied a new set of primers 473 
(28F-combo) with which we observed a significant enrichment of bifidobacteria counts in the 474 
Center 2 (Additional file 7: Figure S1), in agreement with the microbial culture results. 475 
  476 
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Conclusions 477 
In conclusion, our results indicate a role for the gut microbiota in modulating the heterogeneity 478 
apparent in the TSHR-induced model of GD and GO. In our next study we will report the 479 
effects on our induced model of modifying the gut microbiota using antibiotics, probiotics and 480 
fecal material transfer.  481 
Our future studies will investigate whether the presence, absence or amounts of certain bacteria 482 
or yeast have the ability to directly alter the immune balance between the Treg anti-483 
inflammatory response and the Th17-mediated pro-inflammatory response in the gut mucosa 484 
as has been reported in models of other autoimmune diseases [22,46]. Results of these 485 
experiments could then be confirmed by colonization studies in gnotobiotic animals. Factors 486 
such as level of dietary iodine intake and age of mice at immunization, which may both alter 487 
the gut microbiota and/or immune responsiveness, are also warranted. 488 
 489 
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Figure legend   
 
Fig. 1 Comparative analysis of the gut microbiota in independent animal units. a Box and whisker plot 
of the alpha diversity indices for richness (Chao1 and observed OTUs indices) and evenness (Shannon 
index) of the bacterial communities in TSHR immunized mice housed in Center 1 (blue) and Center 2 
(red), respectively. Tukey’s HSD post-hoc: Chao1, P=0.01; Observed OTUs, P<0.001; Shannon, 
P=0.08. b Annotated heatmap based on Spearman distance and Ward hierarchical clustering of the top 
30 genera shows how well the two locations cluster together. Taxonomy explanation includes genera, 
family and phylum, which are entered in order of abundance. Genus abundance is described by the 
change in the intensity of the grey color, as annotated. c Multidimensional scaling plot (MDS) based on 
the weighted Unifrac distances between the two animal units. PERMANOVA with 999 permutations 
P=0.005. d Differentially abundant family from a pairwise comparison with Welch’s t-test with 95% 
confidence intervals (STAMP). e Box and whisker plot culture results from intestinal scraped samples 
derived from TSHR-immunized mice from Center 1 and Center 2. Results are expressed as a Log(x+1) 
transformed colony-forming-units/gram feces (cfu/g). P-values: * P<0.05; ** P<0.001; *** P<0.005. 
 
Fig. 2 Gut microbiota composition in TSHR immunized mice and control mice in Center 2 at final 
timepoint. a Box and whisker plot describing the measurement of alpha diversity (Chao, ACE and 
Shannon indices). b Non-metric dimensional scaling (NMDS) plot of weighted Unifrac distances 
showed a spatial separation of microbial communities according to the immunizations. PERMANOVA 
based on 999 permutations P=0.001. c Boxplot of the phylum counts according to immunizations. 
ANOVA on phylum counts BH adjusted P<0.0001 and pairwise T-test between Bacteroidetes-
Firmicutes counts adjusted P=0.0003. d Non-Metric Dimensional Scaling (NMDS) plot based on 
weighted Unifrac distances shows spatial separation of the microbial community according to the 
immunization and caging within the Center 2. Mice were co-housed according to their immunization at 
a maximum of 4 animals; cages are described by different shapes as in the legend. No significant 
difference in cage effect is observed. PERMANOVA based on cage effect (999 permutations) for all 
comparisons P=0.12. P-values: * P≤0.05; ** P=0.01. 
 
Fig. 3 Time-course analysis of GO preclinical fecal microbiota during the immunization protocol. Box 
and whisker plot of alpha diversity such as Chao, a, and Shannon, b, indices showed differences over 
time. c Phylum dynamics over time and between immunizations. Firmicutes and Bacteroidetes were 
the most abundant phyla, showing differences with time and immunizations. Significant differences 
among timepoints have been observed at the Firmicutes/Bacteroidetes ratio, in particular between the 
baseline T0 and the last timepoint T4, but not related to immunization. A significant difference in the 
ratio was observed after three weeks from the first injection (T1) between βgal and TSHR. P-values: * 
P≤0.05; ** P=0.01. 
 
Fig. 4 Correlating the gut microbiota and disease features in Center 2 TSHR group. a Spearman 
correlation coefficient strength (Rho) of phylum counts from TSHR mice in Center 2. Firmicutes and 
Bacteoridetes showed a strong negative correlation between each other. A positive correlation between 
the one-genus phylum Deferribacteres and the level of thyroid-stimulating antibodies (TSAb) has been 
observed. Correlations with P<0.05 are shown and strength of the Rho coefficient is represented by the 
change in the colour intensity. fT4, free thyroid hormone thyroxine levels; TSAb, thyroid stimulating 
antibodies; TSBAb, thyroid-stimulating blocking antibodies (as a percentage values). b Enriched 
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Firmicutes genus Intestinimonas between Center 1 (blue) and Center 2 (red) showed a strong negative 
correlation with the percentage of thyroid-stimulating blocking antibodies (TSBAbs) at 95% confidence 
interval in Center 1 (Rho=-0.8, P=0.04), but not in Center 2.  
 
Fig. 5 Correlation of the gut microbiota composition with clinical features and differences in Center 2 
mice. a Correlation plot of phyla and the orbital adipogenesis value. Spearman correlation coefficient 
strength (Rho) as indicated by the colored bar. Firmicutes and Bacteoridetes showed a strong negative 
correlation between each other. A positive correlation between Firmicutes and a negative correlation 
with Bacteroidetes OTUs and the adipogenesis value (calculated in the orbit) has been observed. 
Adipogenesis clustered closer to the Firmicutes and Bacteroidetes value according to the complete 
linkage method for hierarchical clustering. Only P<0.05 are shown. b Positive strong correlation of the 
Firmicutes/Bacteroidetes ratio with the adipogenesis value (calculated in the orbit) resulted significant 
in TSHR immunized group but not in the βgal group. c Spearman correlation coefficient (Rho) of genera 
among phyla Bacteroidetes and Firmicutes and the orbital adipogenesis values. The strength of the 
correlation coefficient is represented on x-axis: bars on the left represent a negative correlation 
coefficient, while bars on the right represent a positive correlation coefficient. Correlations with P<0.05 
are shown; order of entrance depends on their P values: * P<0.05; ** P<0.1; *** P<0.005. d Spearman 
correlation coefficient plot of the Box-Cox transformed microbiological counts and disease features in 
Center 2 TSHR immunized mice. Features clustering was according to the complete linkage method for 
hierarchical clustering. Only correlations with P<0.05 are shown and strength of the correlation 
coefficient is represented by the change in the color intensity. fT4, free thyroid hormone thyroxine 
levels; TSAb, thyroid stimulating antibodies; TSBAb, thyroid-stimulating blocking antibodies (as a 
percentage values). 
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1 were more similar to TSHR-immunized mice from Center 2 (P=0.2) than to the βgal (P=0.024) than 
the untreated (P=0.04). (PDF) 
 
Additional file 7: Figure S1. Bifidobacterium counts derived from the 28F-combo primers in the TSHR 
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Schematic representation of the GO immunization protocol and sample collection. Female 
BALB/cOlaHsd, 6-8 weeks old mice were immunized via intramuscular injection and 
electroporation of either the eukaryotic expression plasmid pTriEx1.1Neo-hTSHR 
(hTSHR289) to develop signs of GO (TSHR A-subunit) or the control plasmid pTriEx1.1Neo-
β-gal, as a plasmid-control group (βgal). Each animal received a total of four plasmid injections 
at three week-intervals. All immunized and control mice were sacrificed 9 weeks after the last 
immunization to permit the development of the chronic phase of the disease in the TSHR 
immunized group. Fecal pellets have been collected during the time course of the immunization 
trial from the baseline (T0) and before any other injection until the end of the procedure (T4). 
After euthanasia, the microbial content residing on the colonic mucosa has been collected 
through scraping.   
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Supplementary methods 
Media and conditions for microbial cultures  
The following media, culture conditions and dilutions were used to isolate different bacteria in this 
study: Horse blood agar (Horse blood agar base No.2 (CM0271) with added Defibrinated Horse Blood 
(SR0050); both Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 24 
hours at 36 +/- 1 °C. Dilutions from 10-2 to 10-7 were made and total cell count was measured. 
MacConkey agar No. 3 (CM0115, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic 
conditions for 24 hours at 36 +/- 1 °C. Dilutions from 10-2 to 10-7 were made and Enterobacteriaceae 
(red colonies with bile precipitation and straw coloured colonies) were counted. Slanetz and Bartley 
Medium (CM0377, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 
24 hours at 36 +/- 1 °C. Dilutions from 10-2 to 10-7 were prepared and enterococci (deep red coloured 
colonies) were counted. Brilliance E. coli / coliform selective agar (CM1046, Oxoid, Basingstoke, 
United Kingdom) was incubated under aerobic conditions for 24 hours at 36 +/- 1 °C. Dilutions from 
10-2 to 10-7 were made and E. coli (purple colonies) were counted. Tergitol 7 agar (CM0793, Oxoid, 
Basingstoke, United Kingdom) was incubated under aerobic conditions for 24 hours at 36 +/- 1 °C.  
Dilutions from 10-2 to 10-7 were prepared and coliforms (any color) were counted. Baird Parker agar 
base (CM0275, Oxoid, Basingstoke, United Kingdom) with added 50 ml of Egg Yolk Tellurite 
Emulsion (SR0054, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 
48 hours at 36 +/- 1 °C. Dilutions from 10-2 to 10-7 were made and Staphylococcus aureus (black, shiny 
colonies with white and clear zones) were counted. Anaerobe basal agar (CM0972, Oxoid, Basingstoke, 
United Kingdom) was pre-reduced and incubated under anaerobic conditions for 48 hours at 36 +/- 1 
°C. Dilutions from 10-2 to 10-7 were prepared and total cell count was measured. Each colony was 
checked for aerobic growth and ignored if so. Dichloran Rose-Bengal Chloramphenicol Agar (DRBC 
agar) (CM0727, Oxoid, Basingstoke, United Kingdom) was incubated under aerobic conditions for 48 
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hours at 36 +/- 1 °C. Dilutions from 10-1 to 10-2 were made and total yeast cell count was measured. 
Wilkins-Chalgren anaerobe agar (Code: CM0619, Oxoid, Basingstoke, United Kingdom) with added 1 
vial of G-N Anaerobe Supplement (SR0108) and 25 ml defibrinated blood (SR0050/SR0051, both 
Oxoid, Basingstoke, United Kingdom) was pre-reduced and incubated under anaerobic conditions for 
48 hours at 36 +/- 1 °C.  Dilutions from 10-3 to 10-8 were made and Bacteroides spp. (grey/white colonies 
partially mucoid and with tattered edges) were counted. Each colony was checked for aerobic growth 
and ignored if so. MRS agar (CM0361, Oxoid, Basingstoke, United Kingdom) with added 1 vial of 
polymyxin B supplement (SR0099, Oxoid, Basingstoke, United Kingdom) was pre-reduced and 
incubated under anaerobic conditions for 48 hours at 36 +/- 1 °C. Dilutions from 10-3 to 10-8 were 
prepared and lactobacilli (pale straw coloured colonies) were measured. MRS-X agar (see MRS agar 
added 0.25 g L-cysteine hydrochloride monohydrate, 1 g Lithium chloride and 1.5 g Sodium propionate 
dissolved in 500 ml deionised water) was pre-reduced and incubated under anaerobic conditions for 48 
hours at 36 +/- 1 °C. Dilutions from 10-3 to 10-8 were made and checked for bifidobacteria (small, shiny 
colonies). Alcohol shock anaerobe basal agar was prepared as follows: 1 ml of the 1 g faeces diluted in 
9 ml maximum recovery diluent with glycerol was mixed with 1 ml ethanol (≥98%, Sigma Aldrich, St. 
Louis, Missouri, USA) and rolled for 30 min. Conditions were similar to anaerobe basal agar. Dilutions 
from 10-1 to 10-4 were made and total cell count was measured. Each colony was checked for aerobic 
growth and ignored if so. 
Stability of the faecal microbiota over time 
The function Adonis [Anderson, 2001] implemented in the Vegan package was used to test the 
variations between-samples of the microbial communities (calculated using the weighted Unifrac 
distance) over timepoints and among cages, via a permutational analysis of variance or non-parametric 
MANOVA. The linear predictors and response matrix were as following:  
𝑦𝑖𝑗𝑘 = 𝜇 + 𝑇𝑖 +  𝐼𝑗 + (𝑇 ∗ 𝐼)𝑖𝑗 + 𝐶𝑘  + (𝐶 ∗ 𝑇)𝑘𝑖  + (𝐶 ∗ 𝐼)𝑘𝑗  +  𝑒𝑖𝑗𝑘 
whereas:  
𝑦𝑖𝑗𝑘 is the weighted Unifrac matrix for treatment i, time j and cage k, 
µ is the overall mean; 
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𝑇𝑖 is the effect of the ith time which was set as a class (T0, T1…T4); 
𝐼𝑗 is the type of jth immunization which is represented by either TSHR or βgal;  
𝐶𝑘 is the effect of kth cage which is expressed as a class (C1, C2…C5); 
(𝑇𝐼)𝑖𝑗   (𝐶𝑇)𝑘𝑖 and (𝐶𝐼)𝑘𝑗 represent factorial interactions between time, immunizarions and cage; 
 𝑒𝑖𝑗𝑘 is the vector of the residual effects.  
A pairwise interaction within immunizations, cages and timepoints has been assessed using a built-in 
pairwise PERMANOVA script in R.  
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